Gardasil supplemental application gets priority review designation
Merck & Co., Inc.’s supplemental Biologics License Application for use of Gardasil in women aged 27 through 45 has been accepted by the FDA and designated for priority review.
WHITEHOUSE STATION, New Jersey-Merck & Co., Inc.’s supplemental Biologics License Application for use of Gardasil in women aged 27 through 45 has been accepted by the FDA and designated for priority review. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant] is currently indicated for girls and women age 9 through 26 for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by HPV types 6, 11, 16, and 18.
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.
